China Resources Pharmaceutical Group Limited (the Group), through its wholly-owned subsidiary China Resources Pharmaceutical Investment Company Limited (CR Pharmaceutical Investment), has initiated a potential disposal of approximately 17.87% equity interests in Hefei Tianmai Biotechnology Development Co., Ltd. (Tianmai Biotechnology). The equity interests are held by CR Pharmaceutical Investment and its subsidiary and are being offered in a public tender process on the Shanghai United Assets and Equity Exchange, with a minimum listing price set at around RMB1.42 billion.

According to the announcement dated 9 February 2026, CR Pharmaceutical Investment and its subsidiary currently hold less than 30% of Tianmai Biotechnology’s equity interests. If an intended transferee is identified, relevant transaction agreements are expected to be executed. If no intended transferee emerges, the public tender process will lapse automatically. The Group will comply with the applicable requirements under Chapter 14 of The Stock Exchange of Hong Kong Limited’s Listing Rules once a definitive agreement is signed, if necessary.

As of the date of the announcement, no intended transferee has been identified, and there are no definitive transaction agreements in place. The potential disposal remains subject to successful completion of the public tender process and the execution of relevant agreements. The announcement advises shareholders and potential investors to exercise caution when dealing in the securities of the company.

As stated, the Board of China Resources Pharmaceutical Group Limited comprises Chairman and Executive Director Mr. Bai Xiaosong, Executive Directors Mr. Cheng Jie and Mr. Liu Changan, Non-executive Directors Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan, Mdm. Jiao Ruifang, and Independent Non-executive Directors Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian, and Mr. Shi Luwen.